COVIVAC vaccine(Institute Of Vaccines And Medical Biologicals, Vietnam)

This prospective, single-center, randomized, placebo-controlled (phase 1) and active-controlled (phase 2), observer-blind Phase 1/2 study includes two separate parts.
After completing the phase 1 interim analysis, 2 doses (3mcg and 6mcg) were selected for phase 2.
In Part 2 of this combined Phase 1/2 study, 374 adults aged 18-75 years will be randomized (1:1:1) to AZD1222, or COVIVAC 3 µg being evaluated in Phase 1 or the intermediate dose of COVIVAC 6 µg being selected after consideration of phase 1 results.